SavedAdd your journal

Journals / Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2026 / Volume: 2 Issue: 4

Meme Kanseri Proteom Profilinin Yüzey Geliştirilmiş Lazer Desorpsiyon / İyonizasyon Uçuş Kütle Spektrometrisi (SELDI-TOF MS) ile Belirlenmesi

Yasemin Baskın
Türkan Yiğitbaşı(Medipol Üniversitesi, Tıp Fakültesi, Biyokimya A.D)
Murat Kemal Atahan(Atatürk Eğitim ve Araştırma Hastanesi, 1. Cerrahi Kliniği, İzmir, Türkiye)
Hasan Küpeli(Atatürk Eğitim ve Araştırma Hastanesi, 1. Cerrahi Kliniği, İzmir, Türkiye)
Seyran Yiğit
Ercüment Tarcan(Atatürk Eğitim ve Araştırma Hastanesi, 1. Cerrahi Kliniği, İzmir, Türkiye)
Pages
—
Publication Date
2015-12-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results indicate that there are differences in serum protein expression among the three different groups of patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Surface-enhanced laser desorption/ionization time-of flight mass spectrometry (SELDI-TOF MS) was used to screen serum proteomic profiling to identify protein markers for early breast cancer patients.
📊
Key Findings & Data:Methods: We used metal ion affinity chromatography (IMAC30-Cu) for serum proteome fractionation technique and identify differentially expressed peptides (m/z; P < 0.0001) from benign disease and healthy controls as potential biomarkers of early breast cancer.
💡
Conclusion & Impact:These results indicate that there are differences in serum protein expression among the three different groups of patients.
🔬Design:Article
📍Scope:Comprehensive Sample
⚙️Variables:serum proteomic profiling · SELDI-TOF MS · Breast carcinoma

Abstract

Objective: Surface-enhanced laser desorption/ionization time-of flight mass spectrometry (SELDI-TOF MS) was used to screen serum proteomic profiling to identify protein markers for early breast cancer patients. Methods: We used metal ion affinity chromatography (IMAC30-Cu) for serum proteome fractionation technique and identify differentially expressed peptides (m/z; P < 0.0001) from benign disease and healthy controls as potential biomarkers of early breast cancer. The mass spectra, analyzed using ProteinChip Data Manager Software, distinguished between patients and healthy individuals based on k-nearest neighbor genetic algorithm. We collected 70 serum samples from patients with breast cancer (62 invasive breast carcinoma; 8 ductal carcinoma in situ), 31 bening disease and 37 healthy individuals. Results: Forty two peaks showed statistically significantly different intensities between cases and controls (P<0.05); 10 protein peaks were differentially expressed between the patients and benign disease. These results indicate that there are differences in serum protein expression among the three different groups of patients. Conclusion: SELDI-TOF MS could be used to screen blood samples for the early detection of breast cancer patients. Serum proteomic profiling by SELDI-TOF MS is a novel potential tool for the clinical diagnosis of patients with breast carcinoma.

Özet

AMAÇ: Yüzey geliştirilmiş lazer desorpsiyon / iyonizasyon (SELDI) Uçuş kütle spektrometrisi (TOF MS) kullanılarak erken evre meme kanseri hastalarında serum proteom profilinde protein markerlar tanımlandı.YÖNTEMLER: Serum proteom fraksiyonlarını ayrımlama için metal iyon kromatografi (IMAC30-Cu) kullanıldı ve farklı şekilde eksprese olan peptitler (m / z; p

🔖

Cite This Article

Baskın, Y., Yiğitbaşı, T., Atahan, M. K., Küpeli, H., Yiğit, S., Tarcan, E. (2015). Meme Kanseri Proteom Profilinin Yüzey Geliştirilmiş Lazer Desorpsiyon / İyonizasyon Uçuş Kütle Spektrometrisi (SELDI-TOF MS) ile Belirlenmesi. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Volume: 2 Issue: 4. https://ajindex.com/articles/1195686

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007; 57 (1): 43-669.
  2. Petterson SD, Aebersold RH. Proteomics: First decade and beyond. Nature Genetics Supplement 2003; 33: 311-32.
  3. Baskın Y. Tıpta teknolojik gelişimin neden olduğu kavram değişimleri: kişiselleştirilmiş tıp. Türk Hijyen ve Deneysel Tıp Dergisi, 2007; 64(2): 54-59. 4. Baskın Y. Yigitbası T. Clinical Proteomics of Breast Cancer. Current Genomics, 2010; 11 (7): 528-536.
  4. Celis JE, Gromov P. Proteomics in tranlational cancer research: Toward an integrated approach. Cancer Cell 2003; 3: 9-15.
  5. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002; 48: 1296–1304.
  6. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature, 2008; 452:571– 579.
  7. Becker S, Cazares LH, Watson P et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol, 2004; 11: 907– 914.
  8. Laronga C, Becker S, Watson P et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers, 2003; 19: 229–238
  9. Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer. Mol. Cel. Proteomics, 2006; 5 (10): 1772-1786.
  10. Belluco C, Petricoin EF, Mammano E et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol, 2007; 14: 2470–2476.
  11. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem, 2002; 48: 1296–1304.
  12. Li J, Orlandi R, White CN et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (Kyoto), 2005; 51: 2229– 2235.
  13. Mathelin C, Cromer A, Wendling C et al. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat, 2006; 96: 83–90.
  14. Van Winden AWJ, Gast MCW, Beijnen JH et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics, 2009; 19: 2-4.
  15. Goncalves A, Esterni B, Bertucci F et al. Postoperative serum proteomic profiles may predict metastatic relapse in highrisk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene, 2006; 25: 981–989.
  16. Song J, Patel M, Rosenzweig CN et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ ionization- based immunoassay. Clin Chem, 2006; 52: 1045–1053.
  17. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease peptidome patterns. J Clin Invest, 2006; 116:271–284.
  18. Fung ET, Yip TT, Lomas L et al. Classification of cancer tumor-specific serum types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer, 2005; 115:783-789.
  19. Goldsmith GH Hemostatic changes in patients with malignancy. Int J Hematol, 2001; 73: 151–156.
  20. Shi Q, Harris LN, Lu X et al. Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res, 2006; 5: 2947–2955.
  21. Atahan K, Küpeli H, Gür S ve ark.The value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer. International Journal of Medical Sciences, 2011; 8(2): 148-155. http://edergi.cbu.edu.tr/ojs/index.php/cbusbed isimli
  22. SBED başlıklı eseri bu Creative Commons Alıntı-Gayriticari 4.0
  23. Uluslararası Lisansı ile lisanslanmıştır. yazarın CBU